Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.
Kathryn C ArbourMark G KrisGregory J RielyAi NiKathryn BealMariza DarasSara A HayesRobert J YoungChristopher R RodriguezLinda AhnWilliam PaoHelena A YuPublished in: Cancer (2017)
Pulse/continuous-dose erlotinib produced a 74% overall response rate and a 75% response rate in brain metastases in patients with EGFR-mutant lung cancers and untreated brain metastases. CNS control persisted even after progression elsewhere. Although this regimen did not improve progression-free survival or delay the emergence of EGFR T790M, it prevented progression in the brain and could be useful in situations in which CNS control is critical. Cancer 2018;124:105-9. © 2017 American Cancer Society.
Keyphrases
- brain metastases
- epidermal growth factor receptor
- small cell lung cancer
- tyrosine kinase
- advanced non small cell lung cancer
- papillary thyroid
- free survival
- squamous cell
- blood pressure
- childhood cancer
- blood brain barrier
- white matter
- squamous cell carcinoma
- lymph node metastasis
- brain injury
- subarachnoid hemorrhage
- functional connectivity
- cerebral ischemia